Sartorius AGSARTF -1.83%85 Net Margin % is 6.25% as of Mar. 2026, which is 25% below its 10-year median of 8.38. GuruFocus rates SARTF with a GF Score™ of 85/100 and a GF Value™ of $226.12 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Sartorius AG ranks better than 60.83% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Sartorius AG's Net Income for the
three
months ended in Mar. 2026 was $65 Mil. Sartorius AG's Revenue for the
three
months ended in Mar. 2026 was $1,039 Mil. Therefore, Sartorius AG's net margin for the quarter that ended in Mar. 2026 was 6.25%.
The historical rank and industry rank for Sartorius AG's Net Margin % or its related term are showing as below:
SARTF'
s Net Margin % Range Over the Past 10 Years
Min: 2.48 Med: 8.38 Max: 16.24
Current: 5.63
SARTF's Net Margin % is ranked better than 60.83% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.07
vs SARTF: 5.63
Sartorius AG (OTCPK:SARTF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Sartorius AG Net Margin % Related Terms
Sartorius AG Net Margin % Historical Data
* Premium members only.
The historical data trend for Sartorius AG's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Sartorius AG's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius AG Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's Net Margin % distribution charts can be found below:
* The bar in red indicates where Sartorius AG's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius AG (SARTF) has a Net Margin % of 6.25% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Sartorius AG and its competitors. This is 25% below median its historical median of 8.38. Over the past decade, Sartorius AG's Net Margin % has ranged from 2.48 to 16.24. According to the industry distribution chart, Sartorius AG ranks #320 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 39.2%.
Is Sartorius AG's Net Margin % too high?
Sartorius AG's current Net Margin % of 6.25% is 25% below median its 10-year median of 8.38. Over the past 10 years, this metric has ranged from a low of 2.48 to a high of 16.24. The Medical Devices & Instruments industry median Net Margin % is 2.07. Sartorius AG's value of 6.25% is 201.9% above this industry median. Based on the distribution chart, Sartorius AG ranks #320 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sartorius AG has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's Net Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius AG ranks #320 out of 817 companies for Net Margin %. This puts Sartorius AG in the upper half of its industry. The industry median Net Margin % is 2.07. Sartorius AG's value of 6.25% is 201.9% above this benchmark. Historically, Sartorius AG's own Net Margin % has ranged from 2.48 to 16.24 over the past decade. While the company's 10-year median is 8.38 vs. the industry median of 2.07, Sartorius AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.07, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius AG's current Net Margin % of 6.25% is 201.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Sartorius AG and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius AG's current Net Margin % is 6.25%, which is 25% below median its own 10-year median of 8.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $226.12, compared to a current price of $192.43 — trading 14.9% below its estimated fair value. The current Net Margin % is 6.25%, which is 25% below median its 10-year median of 8.38 and 201.9% above the Medical Devices & Instruments industry median of 2.07. Sartorius AG's overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Sartorius AG (SARTF), the current Net Margin % is 6.25% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius AG (SARTF) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued.
The current stock price of $192.43 is trading 14.9% below its estimated GF Value™ of $226.12.
GuruFocus considers Sartorius AG to be Modestly Undervalued.
Key valuation signals for SARTF:
Net Margin %: 6.25% (25% below median its 10-year median of 8.38)
GF Value™: $226.12 vs. price of $192.43 (14.9% below fair value)
Industry Position: 201.9% above the Medical Devices & Instruments median (#320 of 817)
No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
85GF Score
Get the complete analysis for SARTF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SARTF has been successfully added to your 
